Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT03367702

PHASE3

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Sponsor: NRG Oncology

View on ClinicalTrials.gov

Summary

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

Official title: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

692

Start Date

2018-02-01

Completion Date

2027-12-01

Last Updated

2026-01-15

Healthy Volunteers

Conditions

Stage II Prostate Adenocarcinoma AJCC v7

Interventions

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Inclusion Criteria: * Previously untreated (no local therapy such as surgery, radiation cryotherapy, high-intensity focused ultrasound \[HIFU\], etc.) localized adenocarcinoma of the prostate with the following clinical findings: * Clinical stage by digital rectal exam of either T1c or T2a/b (limited to one side of the gland); (American Joint Committee on Cancer \[AJCC\], version 7) or cT1a-c or 2a or 2b * Stages T1a-T1b are eligible if patient underwent transurethral prostatic resection (TURP) * The patient must meet one of the following 3 criteria: 1) Gleason score must be Gleason 7(3+4) with a PSA \< 20 ng/mL, or 2) Gleason 6 (3+3) with a PSA \> 10 ng/mL and \< 20 ng/mL which is considered intermediate risk and eligible for the study (AJCC, version 7), or 3) Group Grade 1 with a PSA \> 10 ng/mL and \< 20 ng/mL or 2 with a PSA \< 20 ng/mL * If patient is receiving a 5-alpha reductase inhibitor at the time of enrollment, the baseline PSA value may be double the initial value and the medication should be discontinued but a washout period is not required; to be eligible, a PSA drawn while still on the medicine must be: * \< 10 ng/mL if Gleason 7(3+4) (note this patient would be on stratification level 1 if PSA \< 5 ng/mL and stratification level 2 if less than 10 ng/mL) * \> 5 ng/mL and less than 10 ng/mL for Gleason 6(3+3) (note this patient would be on stratification level 3) * The prostate volume must be \< 70 cc as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including magnetic resonance imaging (MRI) or computed tomography (CT) scan * Patients in active surveillance who elect to be treated are eligible if they meet protocol requirements * Age \>= 18 * History and physical including a digital rectal exam 60 days prior to registration * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 60 days prior to registration * MRI of the prostate and pelvis (per institutional standard of care \[SOC\] - should be compliant with PIRADSv2.1 guidelines) within 1 year prior to registration * Bone scan as clinically indicated within 120 days prior to registration * Charlson modified co-morbidity score =\< 4 for patients under 60 and =\< 5 for patients 60 and over 21 days prior to registration * International prostate symptom score (IPSS) of \< 15 21 days prior to registration * The patient must provide study-specific informed consent prior to study entry * Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire * Completion of all items of the EPIC-26 which will be data entered at registration 60 days prior to registration * Only English, Spanish, and French-speaking patients are eligible to participate as these are the only languages EPIC-26 has been validated in Exclusion Criteria: * Definitive clinical or radiologic evidence of metastatic disease; no nodal involvement or evidence of metastatic disease allowed as defined by screening of the pelvis * Definitive T3 disease on MRI * Prior or current invasive malignancy with current evidence of active disease within the past 2 years * Exceptions: Non-melanomatous skin cancer, carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma * Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; must be off treatment for at least 3 years * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * The use of hormonal therapy is not allowed; if the patient is on a 5-alpha reductase inhibitor, then they should be stopped prior to treatment once enrolled onto the study; no washout period is required for this study to participate * Severe, active co-morbidity defined as follows: * Human immunodeficiency virus (HIV) positive with CD4 count \< 200 cells/microliter; Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count \>= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study) * Contraindication to MRI * Cardiac pacemaker or defibrillator * Surgically implanted electrical devices such as spinal stimulation devices or intracranial stimulation devices, cochlear implants, the presence of metallic foreign bodies in the orbits, and incompatible old mechanical heart valves and aneurysm clips

Locations (293)

Mobile Infirmary Medical Center

Mobile, Alabama, United States

Lewis and Faye Manderson Cancer Center

Tuscaloosa, Alabama, United States

Arizona Center for Cancer Care - Gilbert

Gilbert, Arizona, United States

Arizona Center for Cancer Care-Peoria

Peoria, Arizona, United States

Arizona Center for Cancer Care - Scottsdale

Scottsdale, Arizona, United States

Arizona Center for Cancer Care-Surprise

Surprise, Arizona, United States

Arizona Oncology Associates-West Orange Grove

Tucson, Arizona, United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Kaiser Permanente-Anaheim

Anaheim, California, United States

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, United States

Mercy Cancer Center - Carmichael

Carmichael, California, United States

Mercy San Juan Medical Center

Carmichael, California, United States

Kaiser Permanente Dublin

Dublin, California, United States

Mercy Cancer Center - Elk Grove

Elk Grove, California, United States

Fresno Cancer Center

Fresno, California, United States

Marin General Hospital

Greenbrae, California, United States

UC San Diego Moores Cancer Center

La Jolla, California, United States

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, United States

Los Angeles General Medical Center

Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

Memorial Medical Center

Modesto, California, United States

Kaiser Permanente Oakland-Broadway

Oakland, California, United States

Saint Joseph Hospital - Orange

Orange, California, United States

Stanford Cancer Institute Palo Alto

Palo Alto, California, United States

Kaiser Permanente-Rancho Cordova Cancer Center

Rancho Cordova, California, United States

Mercy Cancer Center - Rocklin

Rocklin, California, United States

Rohnert Park Cancer Center

Rohnert Park, California, United States

The Permanente Medical Group-Roseville Radiation Oncology

Roseville, California, United States

Mercy Cancer Center - Sacramento

Sacramento, California, United States

Sutter Medical Center Sacramento

Sacramento, California, United States

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States

Salinas Valley Memorial

Salinas, California, United States

Stanford Cancer Center South Bay

San Jose, California, United States

Kaiser Permanente Medical Center - Santa Clara

Santa Clara, California, United States

Kaiser Permanente Cancer Treatment Center

South San Francisco, California, United States

Gene Upshaw Memorial Tahoe Forest Cancer Center

Truckee, California, United States

Woodland Memorial Hospital

Woodland, California, United States

UCHealth University of Colorado Hospital

Aurora, Colorado, United States

UCHealth Memorial Hospital Central

Colorado Springs, Colorado, United States

Memorial Hospital North

Colorado Springs, Colorado, United States

AdventHealth Porter

Denver, Colorado, United States

Poudre Valley Hospital

Fort Collins, Colorado, United States

Valley View Hospital Cancer Center

Glenwood Springs, Colorado, United States

AdventHealth Littleton

Littleton, Colorado, United States

AdventHealth Parker

Parker, Colorado, United States

Smilow Cancer Hospital Care Center - Guilford

Guilford, Connecticut, United States

Yale University

New Haven, Connecticut, United States

Smilow Cancer Hospital Care Center-Trumbull

Trumbull, Connecticut, United States

Smilow Cancer Hospital Care Center - Waterford

Waterford, Connecticut, United States

Beebe South Coastal Health Campus

Millville, Delaware, United States

Helen F Graham Cancer Center

Newark, Delaware, United States

Christiana Care Health System-Christiana Hospital

Newark, Delaware, United States

Beebe Health Campus

Rehoboth Beach, Delaware, United States

John Fitzgerald Kennedy Medical Center

Atlantis, Florida, United States

Mount Sinai Comprehensive Cancer Center at Aventura

Aventura, Florida, United States

Broward Health North

Deerfield Beach, Florida, United States

Broward Health Medical Center

Fort Lauderdale, Florida, United States

GenesisCare USA - Key West

Key West, Florida, United States

GenesisCare USA - Lakewood Ranch

Lakewood Rch, Florida, United States

Mount Sinai Medical Center

Miami Beach, Florida, United States

GenesisCare USA - Plantation

Plantation, Florida, United States

Grady Health System